Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$3.02 - $4.56 $59,297 - $89,535
-19,635 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$3.92 - $7.48 $16,303 - $31,109
4,159 Added 26.87%
19,635 $88,000
Q4 2021

Feb 10, 2022

SELL
$6.7 - $11.38 $2,860 - $4,859
-427 Reduced 2.69%
15,476 $111,000
Q3 2021

Nov 12, 2021

BUY
$10.11 - $17.56 $10,362 - $17,999
1,025 Added 6.89%
15,903 $171,000
Q2 2021

Aug 05, 2021

SELL
$14.9 - $20.82 $7,405 - $10,347
-497 Reduced 3.23%
14,878 $258,000
Q1 2021

May 06, 2021

SELL
$12.57 - $21.22 $13,198 - $22,281
-1,050 Reduced 6.39%
15,375 $326,000
Q4 2020

Feb 10, 2021

BUY
$8.73 - $14.56 $12,833 - $21,403
1,470 Added 9.83%
16,425 $217,000
Q3 2020

Nov 12, 2020

SELL
$8.56 - $11.6 $29,617 - $40,136
-3,460 Reduced 18.79%
14,955 $132,000
Q2 2020

Aug 13, 2020

BUY
$6.63 - $12.85 $122,091 - $236,632
18,415 New
18,415 $184,000

Others Institutions Holding ICAD

About ICAD INC


  • Ticker ICAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 25,333,900
  • Market Cap $42.1M
  • Description
  • iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, an...
More about ICAD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.